Skip to content

To compare the efficacy and safety of Forskolin eye drops 1% in comparison with Timolol 0.5% in cases of Open Angle Glaucoma.

To compare the efficacy and safety of Forskolin eye drops 1% vis-a-vis Timolol 0.5% in cases of Open Angle Glaucoma.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2013/12/004201
Enrollment
90
Registered
2013-12-10
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Adult male or female subjects with primary open angle glaucoma

Interventions

Intervention1: Forskolin eye drops 1%: Two drops three times a day for 28 days Control Intervention1: Timolol eye drops 0.5%: Two drops three times a day for 28 days

Sponsors

Sami labs Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Adult patients male or female having open angle glaucoma will be included in the study 2 Glaucoma with intra ocular pressure of more than 24 mm/Hg will be included 3 No miotic or other therapy 24 hours before 4 Off systemic therapy for glaucoma for atleast 4 days 5 Informed consent given

Exclusion criteria

Exclusion criteria: 1 Inflammatory ophthalmic dose during the last 3 months 2 Secondary or closed angle glaucoma 3 Bronchial asthma 4 Chronic obstructive pulmonary disease 5 Uncompensated cardiac failure 6 Sinus bradycardia 7 2nd or 3rd degree AV Block 8 Concurrent drug intake for e.g. β blockers, diamox etc 9 Pregnant women

Design outcomes

Primary

MeasureTime frame
Efficacy of Forskolin 1% eye drops as compared to Timolol 0.5% Timepoint: Reduction in Intraocular pressure. Tonometric readings were recorded at 0.5,1,2,3,4,5 and 6 hours.

Secondary

MeasureTime frame
Safety of Forskolin 1% eye dropsTimepoint: Adverse events

Countries

India

Contacts

Public ContactMs Prachi Lad

ClinWorld(P)Ltd

prachi@clinworld.org66981992

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026